{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:04:00Z","timestamp":1792821840178,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020046","name":"Khalifa Bin Zayed Al Nahyan Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020046","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CG Johnson Foundation"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI","award":["K12 CA088084"],"award-info":[{"award-number":["K12 CA088084"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase. This phase Ib dose-\u00adescalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer with RNF43 mutations or RSPO fusions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Patients received once-daily encorafenib and weekly cetuximab, in addition to once-daily WNT974, in sequential dosing cohorts. In the first cohort, patients received 10-mg WNT974 (COMBO10), which was reduced in subsequent cohorts to 7.5-mg (COMBO7.5) or 5-mg (COMBO5) after dose\u2013limiting toxicities (DLTs) were observed. Primary endpoints were incidence of DLTs and exposure to WNT974 and encorafenib. Secondary endpoints were anti-tumor activity and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty patients were enrolled (COMBO10, n = 4; COMBO7.5, n = 6; COMBO5, n = 10). DLTs were observed in 4 patients, including grade 3 hypercalcemia (COMBO10, n = 1; COMBO7.5, n = 1), grade 2 dysgeusia (COMBO10, n = 1), and lipase increased (COMBO10, n = 1). A high incidence of bone toxicities (n = 9) was reported, including rib fracture, spinal compression fracture, pathological fracture, foot fracture, hip fracture, and lumbar vertebral fracture. Serious adverse events were reported in 15 patients, most frequently bone fracture, hypercalcemia, and pleural effusion. The overall response rate was 10% and disease control rate 85%; most patients achieved stable disease as their best response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Concerns surrounding the safety and lack of preliminary evidence of improved anti-tumor activity of WNT974 + encorafenib + cetuximab, compared with previous encorafenib + cetuximab data, ultimately led to study discontinuation. Phase II was not initiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov, NCT02278133<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyad007","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T14:22:46Z","timestamp":1677075766000},"page":"230-238","source":"Crossref","is-referenced-by-count":61,"title":["A Phase Ib\/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E<\/i>-Mutant<i>KRAS<\/i>Wild-Type Metastatic Colorectal Cancer"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"first","affiliation":[{"name":"Vall d\u2019Hebron Hospital Campus, Vall d\u2019Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[{"name":"University Hospitals Gasthuisberg Leuven and KU Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[{"name":"START Madrid, Hospital Universitario HM Sanchinarro , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tai","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Centre Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-730X","authenticated-orcid":false,"given":"Filippo","family":"De Braud","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravit","family":"Geva","sequence":"additional","affiliation":[{"name":"Tel-Aviv Sourasky Medical Center , Tel-Aviv , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T J","family":"van Bussel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, The Netherlands Cancer Institute , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Fiorella Dotti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-0246","authenticated-orcid":false,"given":"Elena","family":"Elez","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron Barcelona Hospital Campus, Vall d\u2019Hebron Institute of Oncology (VHIO), Universitat Aut\u00f2noma de Barcelona , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J","family":"de Miguel","sequence":"additional","affiliation":[{"name":"START Madrid, Hospital Universitario HM Sanchinarro , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Litwiler","sequence":"additional","affiliation":[{"name":"Pfizer , Boulder, CO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Murphy","sequence":"additional","affiliation":[{"name":"Pfizer , La Jolla, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Edwards","sequence":"additional","affiliation":[{"name":"Pfizer , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Karlyle","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2023041012085609100_","author":"World Health Organization","year":"2022"},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11888-017-0354-9","article-title":"Wnt Signaling and colorectal cancer","volume":"13","author":"Schatoff","year":"2017","journal-title":"Curr Colorectal Cancer Rep."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"70589","DOI":"10.18632\/oncotarget.12130","article-title":"RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis","volume":"7","author":"Bond","year":"2016","journal-title":"Oncotarget."},{"issue":"1","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"15270","DOI":"10.1038\/s41598-017-15704-y","article-title":"RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations","volume":"7","author":"Fischer","year":"2017","journal-title":"Sci Rep."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"e000634","DOI":"10.1136\/esmoopen-2019-000634","article-title":"Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer","volume":"5","author":"Kim","year":"2020","journal-title":"ESMO Open."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature11282","article-title":"Recurrent R-spondin fusions in colon cancer","volume":"488","author":"Seshagiri","year":"2012","journal-title":"Nature."},{"issue":"12","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ng.3127","article-title":"RNF43 is frequently mutated in colorectal and endometrial cancers","volume":"46","author":"Giannakis","year":"2014","journal-title":"Nat Genet."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/cancers8060054","article-title":"Control of Wnt receptor turnover by R-spondin-ZNRF3\/RNF43 signaling module and its dysregulation in cancer","volume":"8","author":"Hao","year":"2016","journal-title":"Cancers."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.3390\/ijms21239001","article-title":"The role of BRAF in metastatic colorectal carcinoma-past, present, and future","volume":"21","author":"Djanani","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"6892","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cancers13010137","article-title":"The evolutionary landscape of treatment for BRAF(V600E) mutant metastatic colorectal cancer","volume":"13","author":"Mauri","year":"2021","journal-title":"Cancers."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature."},{"issue":"3","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"issue":"17","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"e35826","DOI":"10.1371\/journal.pone.0035826","article-title":"Receptor tyrosine kinases activate canonical WNT\/\u03b2-catenin signaling via MAP kinase\/LRP6 pathway and direct \u03b2-catenin phosphorylation","volume":"7","author":"Krejci","year":"2012","journal-title":"PLoS One."},{"issue":"4","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrclinonc.2016.171","article-title":"From tumour heterogeneity to advances in precision treatment of colorectal cancer","volume":"14","author":"Punt","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"issue":"50","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"20224","DOI":"10.1073\/pnas.1314239110","article-title":"Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974","volume":"110","author":"Liu","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/fcp.12492","article-title":"Evaluation of antitumor effects of aspirin and LGK974 drugs on cellular signaling pathways, cell cycle and apoptosis in colorectal cancer cell lines compared to oxaliplatin drug","volume":"34","author":"Bagheri","year":"2020","journal-title":"Fundam Clin Pharmacol."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"15945","DOI":"10.1038\/ncomms15945","article-title":"R-Spondin chromosome rearrangements drive Wnt-dependent tumour initiation and maintenance in the intestine","volume":"8","author":"Han","year":"2017","journal-title":"Nat Commun."},{"issue":"31","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"12649","DOI":"10.1073\/pnas.1307218110","article-title":"Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma","volume":"110","author":"Jiang","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","article-title":"Phase 1 study of \u00adsingle-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours","volume":"125","author":"Rodon","year":"2021","journal-title":"Br J Cancer."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.34.15_suppl.3544","article-title":"Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC)","volume":"34","author":"Tabernero","year":"2016","journal-title":"J Clin Oncol."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/2159-8290.CD-16-0795","article-title":"A Phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer","volume":"7","author":"van Geel","year":"2017","journal-title":"Cancer Discov."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fcell.2018.00170","article-title":"Wnt pathway in bone repair and regeneration - what do we know so far","volume":"6","author":"Houschyar","year":"2018","journal-title":"Front Cell Dev Biol."},{"issue":"1","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41413-018-0017-8","article-title":"Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy","volume":"6","author":"Madan","year":"2018","journal-title":"Bone Res."},{"issue":"24","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10637-019-00824-1","article-title":"A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer","volume":"38","author":"Davis","year":"2020","journal-title":"Invest New Drugs."},{"key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","article-title":"Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-\u00adnegative breast cancer","volume":"184","author":"Diamond","year":"2020","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"2023041012085609100_","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1158\/2159-8290.CD-21-0190","article-title":"WNT as a driver and dependency in cancer","volume":"11","author":"Parsons","year":"2021","journal-title":"Cancer Discov."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/230\/49806773\/oyad007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/230\/49806773\/oyad007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T19:02:35Z","timestamp":1701716555000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/3\/230\/7051060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2,23]]},"published-print":{"date-parts":[[2023,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad007","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,2,23]]}}}